Neonatal Sepsis: Addressing the Massive Unmet Need
Executive Summary
Neonatal sepsis remains one of the most devastating conditions affecting newborns worldwide, leading to significant morbidity and mortality despite advances in medical care. The condition, marked by a severe systemic infection in infants, requires rapid and accurate diagnosis to initiate timely treatment. However, current diagnostic methods are often slow, lack sensitivity, and fail to detect a wide range of pathogens, leading to delays in treatment and poor outcomes.
The unmet need in neonatal sepsis diagnostics is profound. Existing tests can take days to return results, and many are unable to identify non-culturable or slow-growing organisms crucial to effective treatment.1–3 This delay in diagnosis can be catastrophic, with every hour of delay in treatment increasing the risk of mortality. Moreover, the broad-spectrum antibiotic treatments often used in the absence of specific pathogen identification can contribute to the growing issue of antibiotic resistance.
Contamination Source Identification (CSI®) offers a groundbreaking solution to this critical problem through its CSI-Dx® diagnostic platform. By leveraging next-generation RNA sequencing, CSI-Dx® can rapidly and accurately identify a wide array of pathogens directly from clinical samples, delivering results within 24 hours. This capability not only improves the speed and accuracy of neonatal sepsis diagnosis but also enables more targeted antimicrobial therapy, reducing reliance on broad-spectrum antibiotics and helping to combat antimicrobial resistance.
This white paper explores the massive unmet need in neonatal sepsis diagnostics, detailing the clinical and economic impacts of delayed and inaccurate diagnosis. It also introduces CSI-Dx® as a transformative solution with the potential to revolutionize how neonatal sepsis is diagnosed and treated, ultimately improving outcomes for the most vulnerable patients.
Introduction
What is Neonatal Sepsis?
Neonatal sepsis is a major public health challenge and one of the leading causes of mortality among neonates globally.4,5 It occurs when a newborn's body responds to an infection with widespread inflammation, leading to potential organ dysfunction and death. Neonates, especially those born preterm or with low birth weight, are at heightened risk due to their underdeveloped immune systems, which struggle to mount an effective defense against pathogens.
Neonatal sepsis is broadly classified into early-onset sepsis (EOS), occurring within the first 72 hours of life, and late-onset sepsis (LOS), which occurs after this period, typically between 3 and 28 days of life.6 EOS is often associated with the vertical transmission of pathogens from the mother, while LOS is more commonly linked to the infant's postnatal environment.6 Global estimates indicate that EOS occurs in 2,469 per 100,000 live births, while LOS occurs in 946 per 100,000 live births, with an overall mortality rate of 17.6%.7
The Challenges in Diagnosing Neonatal Sepsis
Diagnosing neonatal sepsis presents numerous challenges, primarily due to the non-specific nature of its clinical presentation. Symptoms such as temperature instability, respiratory distress, and feeding difficulties are common in many neonatal conditions, making it difficult to distinguish sepsis from other issues6. As a result, clinicians often rely on a combination of clinical judgment, laboratory tests, and microbiological cultures to make a diagnosis.
However, current diagnostic methods are fraught with limitations. Blood cultures, the gold standard for diagnosing sepsis, can take 24 to 72 hours to yield results and have a low sensitivity, particularly when the infection is caused by fastidious or slow-growing organisms8. Moreover, the volume of blood that can be safely obtained from a neonate is limited, which further reduces the likelihood of detecting the causative pathogen. 9,10 Studies have shown that the average volume of blood collected per assay is often less than the recommended 0.5-1 mL, further complicating accurate diagnosis. The delay in obtaining definitive results often forces clinicians to start broad-spectrum antibiotics empirically, which may not be effective against the specific pathogen and contributes to the development of antimicrobial resistance.11
The Need for a New Diagnostic Approach
The limitations of existing diagnostic methods underscore the urgent need for a new approach to diagnosing neonatal sepsis. An ideal diagnostic test would be rapid, highly sensitive, and capable of identifying a wide range of pathogens, including those that are non-culturable or present in low quantities. It would also provide actionable information that could guide targeted antimicrobial therapy, thereby improving patient outcomes and reducing the use of unnecessary antibiotics.
This white paper seeks to address this critical gap by introducing CSI-Dx®, a next-generation sequencing-based diagnostic platform developed by CSI®. CSI-Dx® represents a significant advancement in the field of neonatal sepsis diagnostics, offering the potential to transform the way this deadly condition is identified and treated. Through this white paper, we will explore the current challenges in neonatal sepsis diagnosis, the significant unmet need, and how CSI-Dx® can help bridge this gap, ultimately leading to better outcomes for newborns worldwide.
The Unmet Need in Neonatal Sepsis
Challenges in Early Detection
Neonatal sepsis is a medical emergency that requires immediate intervention. The speed at which sepsis can progress in newborns is alarming, with every hour of delay in initiating appropriate treatment significantly increasing the risk of mortality12–14. Early detection is, therefore, critical to improving survival rates. However, the current landscape of neonatal sepsis diagnosis is marked by significant challenges that hinder timely and accurate detection.7
One of the primary challenges is the non-specific nature of early sepsis symptoms in neonates. Signs such as lethargy, poor feeding, temperature instability, and respiratory distress are often vague and overlap with other neonatal conditions 6. This makes it difficult for clinicians to identify sepsis in its early stages, leading to delays in diagnosis and treatment. The reliance on clinical judgment in these cases, while essential, is often not enough to detect sepsis early and accurately15.
Gaps in Current Diagnostic Approaches
The standard diagnostic approach for neonatal sepsis typically involves blood cultures, along with inflammatory markers such as C-reactive protein (CRP) and procalcitonin.6 While blood cultures remain the gold standard, they come with several limitations that significantly impact their effectiveness in neonatal care. Blood cultures require a relatively large volume of blood, which can be challenging to obtain from a neonate.9,10 Even when sufficient blood is collected, the sensitivity of blood cultures is low, with false negatives being common due to the low bacterial load or the presence of fastidious organisms that are difficult to culture.8
Furthermore, the time required to obtain results from blood cultures, which can range from 24 to 72 hours or more, is often too long to make a timely clinical decision.8 During this period, clinicians are forced to initiate empirical antibiotic therapy, which may not be targeted to the specific pathogen involved. This practice not only increases the risk of inappropriate treatment but also contributes to the growing global issue of antimicrobial resistance.11
The use of inflammatory markers, while helpful, is not without its drawbacks. These markers are non-specific and can be elevated in a variety of conditions, not just sepsis. This lack of specificity can lead to over-treatment with antibiotics, further exacerbating the problem of antibiotic resistance.15
The Clinical and Economic Burden
The challenges associated with diagnosing neonatal sepsis do not only affect patient outcomes but also place a significant burden on healthcare systems. The need for prolonged hospital stays, often in expensive neonatal intensive care units (NICUs), drives up the cost of care. In the United States alone, the total estimated cost for neonatal sepsis treatment was $5.8 billion for 2006, 2009, and 2012 combined.5 These costs are further compounded by the use of broad-spectrum antibiotics and the potential for long-term complications in infants who survive sepsis, including neurodevelopmental impairments and chronic health issues.4,16
The emotional and social impact on families is also profound. The uncertainty and fear associated with a potential sepsis diagnosis, coupled with lengthy hospitalizations and the potential for long-term health consequences, place an immense strain on families. This underscores the need for more accurate, faster diagnostic tools that can reduce the time to diagnosis, limit unnecessary treatments, and improve outcomes for neonates and their families.
The Urgent Need for Innovation
Given these substantial gaps in current diagnostic practices, there is an urgent need for innovative solutions that can address the limitations of existing methods. A new diagnostic approach must be developed that is not only rapid and sensitive but also capable of detecting a wide range of pathogens, including those that are difficult to culture.17,18 Such an approach would not only improve the accuracy of neonatal sepsis diagnosis but also enable more targeted treatments, reducing the reliance on broad-spectrum antibiotics and improving patient outcomes.19
CSI® ’s CSI-Dx® platform is poised to fill this critical gap. By leveraging advanced next-generation sequencing technology, CSI-Dx® can provide rapid, accurate, and comprehensive pathogen detection directly from clinical samples. This capability has the potential to revolutionize neonatal sepsis diagnosis, providing clinicians with the tools they need to make informed, timely treatment decisions, and ultimately saving lives.20
CSI® ’s Diagnostic Platform: A New Era in Neonatal Sepsis Detection
Introduction to CSI-Dx®
In the face of the significant challenges presented by neonatal sepsis, CSI® has developed the CSI-Dx® diagnostic platform, a revolutionary tool designed to meet the urgent need for rapid and accurate pathogen detection in neonates. CSI-Dx® leverages advanced next-generation sequencing (NGS) technology to identify a wide array of pathogens directly from clinical samples. This innovative approach represents a significant departure from traditional diagnostic methods, offering a comprehensive and timely solution to one of the most pressing issues in neonatal care.
How CSI-Dx® Addresses the Unmet Need
CSI-Dx® is uniquely positioned to overcome the limitations of current diagnostic approaches for neonatal sepsis. Traditional methods, such as blood cultures and inflammatory markers, often fail to provide the rapid, specific, and actionable information required to effectively treat this condition. CSI-Dx® changes the diagnostic landscape by offering several key advantages:
Speed: CSI-Dx® delivers results within 24 hours, significantly reducing the time to diagnosis compared to traditional methods, which can take days. This rapid turnaround time is critical in neonatal sepsis, where every hour of delay can increase the risk of mortality.8,14
Sensitivity: The platform is highly sensitive and capable of detecting pathogens that are often missed by conventional methods. Whether dealing with low bacterial loads, fastidious organisms, or non-culturable pathogens, CSI-Dx® provides comprehensive detection that ensures no pathogen goes unidentified18.
Broad Pathogen Detection: CSI-Dx® can identify a wide range of bacterial, viral, and fungal pathogens from a single sample. This comprehensive detection is particularly valuable in neonatal sepsis, where the causative pathogen is often unknown and could be a rare or atypical organism.20
Non-Invasive Testing: Given the small volumes of blood that can be safely obtained from neonates, the ability of CSI-Dx® to work with minimal sample volumes is a significant advantage. The platform’s efficiency in extracting and analyzing nucleic acids from small samples minimizes the burden on these vulnerable patients.9,10
Actionability: Beyond pathogen identification, CSI-Dx® provides detailed information on antimicrobial resistance, enabling clinicians to tailor antibiotic therapy to the specific pathogen detected. This targeted approach reduces the reliance on broad-spectrum antibiotics, helping to combat the growing issue of antimicrobial resistance.11
Clinical Validation and Potential Impact
CSI® has conducted rigorous clinical validation studies to ensure the effectiveness and reliability of CSI-Dx® in diagnosing neonatal sepsis. Early results demonstrate that CSI-Dx® not only matches but often exceeds the sensitivity and specificity of traditional blood cultures. In cases where traditional methods returned negative or inconclusive results, CSI-Dx® was able to detect pathogens, leading to earlier and more accurate diagnoses.18
In practical terms, the implementation of CSI-Dx® in clinical settings has the potential to transform neonatal care. By providing rapid and reliable diagnostic information, CSI-Dx® empowers clinicians to make informed treatment decisions quickly, reducing the time to appropriate therapy and improving patient outcomes. This technology not only holds promise for improving survival rates but also for reducing the long-term complications associated with neonatal sepsis.17,21
Case Examples and Future Directions
To illustrate the impact of CSI-Dx®, consider a hypothetical case: A neonate presents with non-specific symptoms suggestive of sepsis. Traditional diagnostic methods, including blood cultures, fail to identify the causative pathogen, delaying treatment and increasing the risk of adverse outcomes. However, using CSI-Dx®, the pathogen is identified within 24 hours, allowing for targeted antimicrobial therapy that improves the infant’s chances of survival and reduces the length of the hospital stay.17,18
Looking ahead, CSI® is committed to further advancing CSI-Dx® through ongoing research and clinical trials. The platform’s capabilities extend beyond neonatal sepsis, offering potential applications in other areas of infectious disease diagnosis. CSI® is dedicated to ensuring that CSI-Dx® becomes a standard tool in neonatal care, helping to save lives and improve outcomes for the most vulnerable patients.
Impact on Healthcare and Patient Outcomes
Reducing Mortality and Morbidity
One of the most critical factors in improving outcomes for septic neonates is the speed at which appropriate treatment can be initiated. Traditional diagnostic methods, such as blood cultures, often delay treatment decisions due to their slow turnaround times and limited sensitivity.6,8 This delay can be life-threatening, as neonatal sepsis progresses rapidly, with mortality rates increasing by approximately 8% for each hour that appropriate treatment is delayed.14,22
CSI-Dx® addresses this issue head-on by providing diagnostic results within 24 hours, allowing clinicians to start targeted antimicrobial therapy much sooner. This rapid response not only improves the likelihood of survival but also reduces the risk of long-term complications such as neurodevelopmental impairments, chronic lung disease, and other sequelae associated with sepsis. By enabling early and accurate diagnosis, CSI-Dx® can help reduce the overall burden of neonatal sepsis, leading to better health outcomes for newborns.11,17,18
Economic Benefits
The economic impact of neonatal sepsis is substantial, with prolonged hospital stays in neonatal intensive care units (NICUs) and extensive use of healthcare resources driving up costs. In the United States alone, the cost of treating neonatal sepsis is estimated to be in the billions of dollars annually, a figure that is only expected to rise as the incidence of antimicrobial resistance increases.4
CSI-Dx® offers a solution that not only improves clinical outcomes but also has the potential to reduce healthcare costs. By providing rapid and accurate diagnostics, CSI-Dx® can help reduce the length of hospital stays by enabling quicker initiation of appropriate therapy, thereby decreasing the need for prolonged NICU care. Moreover, the platform’s ability to guide targeted antimicrobial therapy can reduce the use of broad-spectrum antibiotics, lowering the risk of developing and spreading antibiotic-resistant bacteria. This targeted approach not only improves patient outcomes but also helps control costs associated with the overuse of antibiotics and the treatment of resistant infections.1,11,17
The economic benefits extend beyond direct healthcare costs. By reducing the long-term complications associated with neonatal sepsis, CSI-Dx® can also lessen the financial burden on families and society. Children who survive sepsis without significant long-term complications are more likely to require fewer healthcare resources in the future and to lead healthier, more productive lives.21
Supporting Healthcare Providers
Neonatal sepsis is a challenging condition to diagnose and treat, often requiring healthcare providers to make critical decisions with limited information. The uncertainty associated with current diagnostic methods can lead to over-treatment, unnecessary use of antibiotics, and increased stress for both clinicians and families.6,15 CSI-Dx® provides a powerful tool that supports healthcare providers by offering clear, actionable diagnostic information that can guide treatment decisions with greater confidence.
The platform’s ability to rapidly identify pathogens and their resistance profiles allows clinicians to tailor treatment to the specific needs of each patient, reducing the guesswork and improving the precision of care. This not only benefits the patient but also enhances the overall efficiency of the healthcare system, as resources can be allocated more effectively, and the potential for errors or unnecessary interventions is reduced.
Moreover, by improving diagnostic accuracy and reducing the time to diagnosis, CSI-Dx® can help alleviate some of the emotional and psychological burden on families, who often face prolonged periods of uncertainty while waiting for diagnostic results.1,21 The knowledge that their child is receiving the most accurate and timely care available can provide immense relief to families during what is often one of the most stressful periods of their lives.
Conclusion
CSI®’s Vision for the Future
CSI® is at the forefront of addressing this critical unmet need through its CSI-Dx® diagnostic platform. By leveraging cutting-edge next-generation sequencing technology, CSI-Dx® offers a rapid, accurate, and comprehensive solution to the challenges of neonatal sepsis diagnosis. This platform is not just a technological advancement; it represents a paradigm shift in how neonatal sepsis is approached, offering clinicians the tools they need to make informed, timely treatment decisions that can save lives and reduce the long-term impacts of sepsis.
CSI® is committed to continuing its leadership in this field, with ongoing research and development aimed at expanding the capabilities of CSI-Dx® and further validating its clinical utility. Our vision is to make CSI-Dx® the standard of care in neonatal sepsis diagnostics, ensuring that every newborn has access to the best possible diagnostic tools, and that no child suffers unnecessarily from delayed or inaccurate diagnosis.
As we stand on the brink of a new era in neonatal care, CSI® calls upon healthcare providers, policymakers, and investors to support the widespread adoption of advanced diagnostics like CSI-Dx®. By doing so, we can collectively improve outcomes for newborns, reduce the burden on healthcare systems, and take significant steps toward eradicating the threat of neonatal sepsis.
The time for change is now. Together, we can ensure that every newborn receives the timely, accurate diagnosis they deserve, and that neonatal sepsis becomes a condition that is not feared, but effectively managed and controlled. CSI® is proud to be a part of this mission, and we are dedicated to working with our partners to make this vision a reality.
References:1. Boscarino G, Romano R, Iotti C, Tegoni F, Perrone S, Esposito S. An Overview of Antibiotic Therapy for Early- and Late-Onset Neonatal Sepsis: Current Strategies and Future Prospects. Antibiotics. 2024;13(3):250. doi:10.3390/antibiotics130302502. Créixems MR, Fron C, Muñoz P, Sánchez C, Peláez T, Bouza E. Use of anaerobically incubated media to increase yield of positive blood cultures in children: Pediatr Infect Dis J. 2002;21(5):443-446. doi:10.1097/00006454-200205000-000253. Popescu CR, Cavanagh MMM, Tembo B, et al. Neonatal sepsis in low-income countries: epidemiology, diagnosis and prevention. Expert Rev Anti Infect Ther. 2020;18(5):443-452. doi:10.1080/14787210.2020.17328184. Fleischmann-Struzek C, Goldfarb DM, Schlattmann P, Schlapbach LJ, Reinhart K, Kissoon N. The global burden of paediatric and neonatal sepsis: a systematic review. Lancet Respir Med. 2018;6(3):223-230. doi:10.1016/S2213-2600(18)30063-85. Bohanon FJ, Nunez Lopez O, Adhikari D, et al. Race, Income and Insurance Status Affect Neonatal Sepsis Mortality and Healthcare Resource Utilization. Pediatr Infect Dis J. 2018;37(7):e178-e184. doi:10.1097/INF.00000000000018466. Simonsen KA, Anderson-Berry AL, Delair SF, Davies HD. Early-Onset Neonatal Sepsis. Clin Microbiol Rev. 2014;27(1):21-47. doi:10.1128/CMR.00031-137. Fleischmann C, Reichert F, Cassini A, et al. Global incidence and mortality of neonatal sepsis: a systematic review and meta-analysis. Arch Dis Child. 2021;106(8):745-752. doi:10.1136/archdischild-2020-3202178. Doern GV, Carroll KC, Diekema DJ, et al. Practical Guidance for Clinical Microbiology Laboratories: A Comprehensive Update on the Problem of Blood Culture Contamination and a Discussion of Methods for Addressing the Problem. Clin Microbiol Rev. 2019;33(1):e00009-19. doi:10.1128/CMR.00009-199. Neal PR, Kleiman MB, Reynolds JK, Allen SD, Lemons JA, Yu PL. Volume of blood submitted for culture from neonates. J Clin Microbiol. 1986;24(3):353-356. doi:10.1128/jcm.24.3.353-356.198610. Singh MP, Balegar V KK, Angiti RR. The practice of blood volume submitted for culture in a neonatal intensive care unit. Arch Dis Child - Fetal Neonatal Ed. 2020;105(6):600-604. doi:10.1136/archdischild-2019-31808011. Fjalstad JW, Esaiassen E, Juvet LK, Van Den Anker JN, Klingenberg C. Antibiotic therapy in neonates and impact on gut microbiota and antibiotic resistance development: a systematic review. J Antimicrob Chemother. 2018;73(3):569-580. doi:10.1093/jac/dkx42612. CDC. Sepsis Is The Body’s Extreme Response To An Infection. Centers for Disease Control and Prevention. August 24, 2022. Accessed March 23, 2023. https://www.cdc.gov/sepsis/what-is-sepsis.html13. Rhee C, Wang R, Zhang Z, et al. Epidemiology of Hospital-Onset Versus Community-Onset Sepsis in U.S. Hospitals and Association With Mortality: A Retrospective Analysis Using Electronic Clinical Data. Crit Care Med. 2019;47(9):1169-1176. doi:10.1097/CCM.000000000000381714. Schulman J, Benitz WE, Profit J, et al. Newborn Antibiotic Exposures and Association With Proven Bloodstream Infection. Pediatrics. 2019;144(5):e20191105. doi:10.1542/peds.2019-110515. Wynn JL. Defining neonatal sepsis. Curr Opin Pediatr. 2016;28(2):135-140. doi:10.1097/MOP.000000000000031516. Danna DM. Hospital Costs Associated with Sepsis Compared with Other Medical Conditions. Crit Care Nurs Clin North Am. 2018;30(3):389-398. doi:10.1016/j.cnc.2018.05.00717. Chen L, Zhao Y, Wei J, et al. Metagenomic Next-Generation Sequencing for the Diagnosis of Neonatal Infectious Diseases. Le Goff J, ed. Microbiol Spectr. 2022;10(6):e01195-22. doi:10.1128/spectrum.01195-2218. Zhang R, Zhuang Y, Xiao Z hui, et al. Diagnosis and Surveillance of Neonatal Infections by Metagenomic Next-Generation Sequencing. Front Microbiol. 2022;13:855988. doi:10.3389/fmicb.2022.85598819. Agudelo-Pérez S, Fernández-Sarmiento J, Rivera León D, Peláez RG. Metagenomics by next-generation sequencing (mNGS) in the etiological characterization of neonatal and pediatric sepsis: A systematic review. Front Pediatr. 2023;11:1011723. doi:10.3389/fped.2023.101172320. Li C, Wang Y. Progress in the application of metagenomic next-generation sequencing in pediatric infectious diseases. Pediatr Neonatol. 2022;63(5):445-451. doi:10.1016/j.pedneo.2022.03.01421. Giannoni E, Dimopoulou V, Klingenberg C, et al. Analysis of Antibiotic Exposure and Early-Onset Neonatal Sepsis in Europe, North America, and Australia. JAMA Netw Open. 2022;5(11):e2243691. doi:10.1001/jamanetworkopen.2022.4369122. Dellinger RP, Levy MM, Carlet JM, et al. Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008: Crit Care Med. 2008;36(1):296-327. doi:10.1097/01.CCM.0000298158.12101.41
